Almost all cervical cancer cases (about 99%) are linked to persistent infection with high-risk types of the human papillomavirus (HPV), a common virus transmitted through sexual contact. In Nigeria, the burden is significant, with an estimated 12,075 new cases and 7,968 deaths recorded annually. Over 60 million women aged 15 and older are considered at risk, and nearly 70% of cases are associated with HPV types 16 and 18.
The Viral Social Media Claim
In February 2026, an X user, Ba sing slay (@kigutasheilaa), shared a post claiming that Pap smears are not the only way to test for cervical cancer and that menstrual blood can be used for screening with equal accuracy.
As of Feb. 6, 2026, the post had generated 171 comments, 2,900 reposts, 34,000 likes, and 2,500 bookmarks. The claim sparked excitement and debate, with some users questioning why women had endured the discomfort of Pap smears if a simpler alternative existed.
Given the public health implications and the post’s virality, DUBAWA examined the evidence behind the claim.
Understanding Cervical Cancer Screening
Cervical cancer screening aims to detect precancerous changes in cervical cells before they develop into cancer. Early detection significantly improves treatment outcomes.
According to the National Cancer Institute, there are three main screening methods:
- HPV Test: Detects high-risk HPV types that can cause cervical cancer.
- Pap Test (Pap Smear): Examines cervical cells for abnormalities that may develop into cancer.
- HPV/Pap Co-test: Combines both methods for higher accuracy.
The Pap smear has a sensitivity of about 50%–75% and specificity of 90%–95% for detecting precancerous changes. Although a single Pap test may miss some abnormalities, its effectiveness improves with regular screening.
HPV testing performs better, with sensitivity rates above 90%–95%. When combined with Pap testing (co-testing), detection accuracy exceeds 95% for significant precancerous lesions, making it one of the most reliable screening strategies currently available.
What Does Research Say About Menstrual Blood Testing?
A limited number of studies have explored whether menstrual blood could serve as an alternative sample for detecting HPV.
A systematic review assessing menstrual blood for HPV detection reported sensitivity ranging from 82.8% to 97.7% and specificity between 50% and 98% for detecting cervical intraepithelial neoplasia or HPV infection. These findings suggest potential diagnostic value.
Another large-scale study conducted in China examined menstrual blood collected via sanitary pads from over 3,000 women and compared the results with clinician-collected cervical samples. The researchers found comparable sensitivity in detecting precancerous abnormalities, although specificity was somewhat lower.
While experts described the findings as promising, they emphasized that the method remains in the research stage and requires further validation before being integrated into routine screening programmes.
Importantly, the reported accuracy of menstrual blood testing varies widely across studies. In contrast, HPV testing and HPV/Pap co-testing have been extensively validated through decades of research and are globally endorsed by medical authorities.
Expert Opinions
To clarify the claim, DUBAWA consulted medical professionals.
Sunday Idoko, a gynaecologist in Garki, explained that current HPV screening relies on samples collected directly from the cervix through cervical scrapings. While research into alternative sampling methods exists, he noted that menstrual blood testing remains an emerging approach and has not replaced established screening procedures.
Lynda Agim, another gynaecologist, stated that Pap smears remain the standard screening method. She explained that if abnormalities are detected, a cervical biopsy is performed to confirm cancer through histological examination.
Xavier Bosch, a researcher at the Catalan Institute of Oncology, described menstrual blood testing research as “very pioneering” but still in an early phase, with unclear clinical applications. He noted that while menstrual blood may contain detectable viral markers, further studies must determine whether its performance matches validated DNA testing methods using established samples.
Conclusion
The claim that menstrual blood testing is “just as accurate” as a Pap smear for cervical cancer screening is misleading.
Although preliminary studies suggest menstrual blood may have potential as a screening tool, the approach remains experimental and has not been approved as a replacement for clinically validated methods such as Pap smears, HPV testing, or HPV/Pap co-testing.
For now, medically approved screening techniques remain the most reliable and recommended options for preventing and detecting cervical cancer early.